Log In
Print
BCIQ
Print
Print this Print this
 

Lusefi, luseogliflozin (TS-071)

  Manage Alerts
Collapse Summary General Information
Company Taisho Pharmaceutical Holdings Co. Ltd.
DescriptionOral sodium-glucose cotransporter 2 (SGLT2) inhibitor
Molecular Target Sodium-glucose cotransporter 2 (SGLT2)
Mechanism of ActionSodium-glucose cotransporter 2 (SGLT2) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationDiabetes
Indication DetailsTreat Type I and Type II diabetes; Treat Type II diabetes
Regulatory Designation

Japan - Standard Review (Treat Type II diabetes)

Partner

Novartis AG


 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today